Advertisement

FDA Advisers Recommend Approval of Two Antibiotics — Physician’s First Watch

Medical News |
April 2, 2014

FDA Advisers Recommend Approval of Two Antibiotics

By Kelly Young

A panel of advisers to the FDA has voted unanimously to recommend approval of two drugs to treat serious Gram-positive acute bacterial skin infections, including methicillin-resistant Staphylococcus aureus, Reuters reports.

Tedizolid (to be marketed as Sivextro) is intended to be used once a day as an intravenous or oral treatment. This drug can be given less often and for shorter time periods and could have fewer side effects than linezolid (Zyvox), one of the current options.

Dalbavancin (to be marketed as Dalvance) would be given on days 1 and 8. Advisers expressed concern about patients receiving the second dose. They also recommended that the manufacturer conduct post-marketing safety studies on dalbavancin's potential to cause liver problems.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement